KEVIN SIEWERS: Open Payments
NPI 1215056221 · DENVILLE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$38,945 in 108 payments from 10 companies in 2025. Trend: 2023 $44,517 · 2024 $62,594 · 2025 $38,945
Speaker / faculty: $26,133Consulting: $5,625Food & beverage: $3,605Travel & lodging: $3,583
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 35 | $22,872 |
| Otsuka America Pharmaceutical, Inc. | 26 | $8,102 |
| Teva Pharmaceuticals USA, Inc. | 21 | $6,918 |
| Alkermes, Inc. | 10 | $283 |
| E.R. Squibb & Sons, L.L.C. | 6 | $263 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $225 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $105 |
| Janssen Scientific Affairs, LLC | 1 | $88 |
| Lundbeck LLC | 3 | $71 |
| Janssen Pharmaceuticals, Inc | 1 | $19 |
Products named: INGREZZA, ABILIFY MAINTENA, UZEDY, REXULTI, ABILIFY ASIMTUFII, COBENFY, CAPLYTA, ARISTADA.
Industry payments across NJ — which companies pay providers there.
